IP Library Granted Patent US 7,838,289
Granted Patent B2
US 7,838,289 · App. 10/467,963 · Granted Nov 23, 2010

Assay utilizing multipotent adult stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,289
App. No.
10/467,963
Granted
Nov 23, 2010
Kind
B2
Abstract

The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.

Claims (9)

1. A method for identifying an agent that is a differentiation factor, the method comprising:

(a) contacting (1) a desired agent with (2) isolated expanded human multipotent, non-embryonic, non-germ, cells that can differentiate into at least one cell type of each of the endodermal, ectodermal and mesodermal embryonic lineages and express telomerase; and

(b) determining whether the agent of step (a) affects differentiation of the telomerase-expressing cells into a desired differentiated progeny, where affecting differentiation indicates an agent that is a differentiation factor, wherein the telomerase-expressing cells have undergone at least 10-40 cell doublings in culture.

2. The method of claim 1 wherein the telomerase-expressing cells express oct3/4.

3. The method of claim 1 , wherein differentiation is into an endodermal cell type.

4. The method of claim 1 , wherein differentiation is into a mesodermal cell type.

5. The method of claim 1 , wherein differentiation is into an ectodermal cell type.

6. The method of claim 1 , wherein the telomerase-expressing cells have undergone greater than 40 cell doublings.

7. The method of claim 1 , wherein the effect on differentiation is assayed by changes in protein expression, RNA expression, or morphology.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →
CHANGE OF NAME Recorded Feb 14, 2008
From: ATHERSYS, INC.
To: ABT HOLDING COMPANY
Reel/Frame 020519/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2008
From: REGENESYS, LLC
To: ATHERSYS, INC.
Reel/Frame 020510/0045 →
MERGER Recorded Feb 13, 2008
From: MCL LLC
To: REGENESYS, LLC
Reel/Frame 020502/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2003
From: VERFAILLIE, DR. CATHERINE M.; FURCHT, DR. LEO; REYES, DR. MORAYMA
To: MCL, LLC; REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 014630/0170 →